Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Regulatory news · October 15, 2026

If FDA finalizes the 503B GLP-1 exclusion: what changes, and what doesn't

Released: · Last reviewed:

Still pending: what a final decision would touch, what it would leave alone, and who makes your medication.

As of October 15, 2026, FDA has not finalized its April 30, 2026 proposal to leave tirzepatide, semaglutide and liraglutide off the 503B bulks list. A final decision would stop 503B outsourcing facilities compounding them from bulk ingredients. 503A pharmacies follow separate rules; of 31 priced programs we track, one says a 503B facility may fill orders.

The proposal often gets shortened to "FDA is banning compounded GLP-1s." It is narrower, and whether it touches you depends on a fact many programs never print: what kind of pharmacy makes your medication.

Where the proposal stands on October 15, 2026

So, 77 days after comments closed, nothing has changed in law. Our newsroom will log a final notice.

What a final decision would change

A 503B outsourcing facility registers with FDA, follows CGMP manufacturing rules and may make batches without patient-specific prescriptions. It may compound from a bulk drug substance only if that substance is on the 503B bulks list or the drug is on FDA's drug shortage list. A final "not on the list" decision closes the first route for these three molecules.

In practice, a 503B facility could not make these drugs from raw active ingredient unless the drug went back into shortage, and a program sourcing from one would need another supplier. That is the whole direct effect.

What it would not change

503A pharmacies run on a different section of the law. A state-licensed 503A pharmacy compounds for a named patient's prescription under state board oversight. Section 503A has its own bulk-ingredient rules and bars compounding drugs that are essentially copies of a commercially available drug regularly or in inordinate amounts. The 503B bulks decision does not rewrite those rules. See our 503A vs 503B guide.

Nothing becomes FDA-approved. Compounded tirzepatide and semaglutide are not FDA-approved and are not generic Zepbound, Mounjaro, Wegovy or Ozempic, from either pathway.

Enforcement does not wait for this rule. FDA warning letter 738238, dated September 18, 2026 and posted September 22, went to Empower Clinic Services, LLC dba Empower Pharmacy. FDA wrote that its tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and that "the volume of products you are producing suggests that differences ... are pretextual." It also cited sterile products "prepared, packed, or held under insanitary conditions." Both sections of the law limit essentially copies, so a pharmacy can sit outside the 503B question and still face this one.

What our tracked programs disclose about pharmacy type

We checked the pharmacy statements on the pages behind every price in our October 15, 2026 price index (31 priced programs), plus three unpriced programs. We record 503A or 503B only when the provider's own page says so.

Who makes the medication, per each program's own pagesRead October 15, 2026 unless another date is shown · basis: the page's words, not our inference · seller domain in brackets
ProgramPharmacy named on the pageType, as the page states itRead
NexLife (nexlife.us)Absolute Pharmacy (Lutz, FL); Premium Compounding (Decatur, AL); Boudreaux's New Drug Store (Lake Charles, LA), on the standard plan pagesState-licensed 503A (plan pages)2026-10-15
SnagRx (snagrx.com)Red Rock Compounding Pharmacy; Health Warehouse; Precision Medicine; Triad Rx503A ("US based 503A compounding pharmacies")2026-10-15
Embody (joinem.co)The same four pharmacies503A, as recorded in our index2026-10-15
NextMeds (nextmeds.com)The same four pharmaciesNot stated2026-10-15
NewMeMeds (newmemeds.com)The same four pharmaciesNot stated2026-09-20
Join Josie (joinjosie.com)Strive Pharmacy (month-to-month); Casa Pharma or Foothills (multi-month)Not stated2026-10-15
Telos RX (telosrx.com)VialsRX (Houston, TX); Jungle Jim's Pharmacy / F&F Pharmacies Inc (Ohio)Not stated2026-10-15
He & She MD (heandshemd.com)Jungle Jim's Pharmacy (F&F Pharmacies Inc); GoGoMeds (Specialty Medical Drugstore LLC)Not stated2026-10-15
GobyMeds (gobymeds.com)None"503A or 503B pharmacy partner, licensed in your state"2026-10-15
Alloy (myalloy.com)None"licensed compounding pharmacies" under "state pharmacy board oversight"2026-10-15
Collective (collective.org)None"state-licensed US pharmacy"2026-10-15
Mondae (mondae.com)None"FDA-registered U.S. pharmacy" (no 503 type given)2026-10-15
19 other priced programs: Bodybuilding Health+, bmiMD, CoreAge Rx, Eden, Enhance.MD, Found, Fridays, Ivím Health, MyDrHank, Pallas Health, Ready Med, ShedRx, SkinnyRx, Sprout Health, Strut Health, TelePep, WellMedr, Yucca Health, yourEraNone recordedNone recorded2026-08-27 to 2026-10-15
Henry Meds (henrymeds.com), unpricedNone"503(A) Compounding Pharmacy or 503(B) Outsourcing" facility2026-10-15
BreezeMeds; Synergy Rx, unpricedBelmar Pharmacy; Strive Pharmacy; Epiq Scripts; Casa Pharma RxNot stated2026-09-17

Across the 31 priced programs, 8 name at least one pharmacy, and 3 of those are stated or recorded as 503A. One (GobyMeds) says its partner may be 503A or 503B without naming it. Three describe their pharmacies only in general terms, and 19 show no name or type on the pages we read. "FDA-registered" alone does not say which pathway a pharmacy uses.

Two supply-risk patterns: four storefronts (Embody, SnagRx, NewMeMeds, NextMeds) list the same four pharmacies, so one pharmacy problem could reach all four. And Join Josie's pharmacy depends on the plan length you choose.

What this means for you

If your program says "503A or 503B"

GobyMeds and Henry Meds both leave room for a 503B outsourcing facility. That group is what a final decision could reach. Ask which facility fills your order and what happens to your remaining supply if a 503B source has to stop. The money matters: GobyMeds' tirzepatide starter bundle is $399 for 12 weeks ($399 ÷ 3 = $133 a month), and its pricing page says "all prescriptions are final sale and non-refundable."

If you are about to prepay a year

Size your exposure first. Two 12-month tirzepatide plans in our index: NexLife at $115 × 12 = $1,380, and Join Josie at a $2,799 plan total ($233.25 a month). If treatment stops after three months, nine months remain: 9 × $115 = $1,035 on NexLife, and $2,799 × 9 ÷ 12 = $2,099.25 on Join Josie.

What comes back depends on written terms. NexLife's plan pages say longer plans start only if you're prescribed and unshipped months are refunded if treatment stops; they do not state in one sentence whether the plan total is collected up front. Join Josie's pages say "prescription costs generally cannot be refunded once your order is filled", so ask how unshipped months are handled before paying. Flexibility costs something: NexLife month-to-month is $129, so a year is $1,548, or $168 more than the 12-month plan. Our prepaid-plan analysis runs that trade.

If your program names no pharmacy

That is 19 of 31 priced programs. Ask for the pharmacy's legal name and address, then follow our pharmacy verification steps and check the compounding pharmacy records.

Checklist before you pay

Evidence status. Regulatory status checked October 15, 2026; pharmacy statements quoted from provider pages on the dates shown. Consumer education, not legal or medical advice.

Frequently asked questions

Has FDA finalized the 503B GLP-1 exclusion?

No. As of October 15, 2026, a Federal Register search found no final notice. FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list, and comments closed July 30, 2026. FDA's bulks list page is still dated May 16, 2024.

Would a final decision ban compounded tirzepatide and semaglutide?

No. It would stop 503B outsourcing facilities from compounding these drugs from bulk ingredients unless the drug returned to FDA's shortage list. Patient-specific compounding by state-licensed 503A pharmacies falls under section 503A, which has separate rules, including limits on essentially copies of approved drugs. Compounded versions are not FDA-approved either way.

How do I know whether my program uses a 503A or 503B pharmacy?

Ask the program for the pharmacy's name, address and pathway in writing. Of 31 priced programs we track, 8 name a pharmacy and 3 of those are stated or recorded as 503A; GobyMeds says 503A or 503B. Verify a 503B claim on FDA's outsourcing facility list and a 503A license with the state board.

What does the Empower warning letter have to do with the 503B proposal?

They are separate actions. Warning letter 738238, dated September 18, 2026, told Empower Pharmacy that its tirzepatide/niacinamide and semaglutide/cyanocobalamin products appear to be essentially copies of FDA-approved products and cited insanitary conditions. It shows FDA enforcing existing compounding limits now, without waiting for a final 503B bulks decision.

Should I avoid a 12-month prepaid plan while the decision is pending?

Not automatically, but size the exposure. If treatment stops after three months, nine months remain: $1,035 on NexLife's 12-month tirzepatide plan ($115 a month) or $2,099.25 on Join Josie's $2,799 plan. Get the refund rule for unshipped months in writing first.

Primary sources